Erasca Securities Fraud Class Action
Analysis based on 193 articles · First reported Jun 11, 2026 · Last updated Aug 10, 2026
The revelations caused Erasca's stock to plummet over 45%, erasing over $2.8 billion in market value, and triggered multiple securities class actions. The litigation and regulatory scrutiny could further depress Erasca's stock and raise concerns about the viability of its lead drug candidate, while Revolution Medicines may benefit from competitive advantage.
A securities class action lawsuit has been filed against Erasca (NASDAQ: ERAS) alleging that the company and certain executives made false and misleading statements regarding its lead oncology candidate, ERAS-0015, a pan-RAS molecular glue. The class period is January 14, 2025 through April 26, 2026. The complaint alleges that Erasca improperly compared preclinical data of ERAS-0015 to Revolution Medicines' RMC-6236, failed to disclose risks of patent infringement and trade secret misappropriation, and downplayed safety risks. On April 27, 2026, Erasca disclosed that Revolution Medicines had accused it of patent infringement and trade secret misappropriation, and later that day reported preliminary Phase 1 data including a patient death. The stock fell over 45% on April 28, wiping out over $2.8 billion in market capitalization. Multiple law firms have filed or announced investigations, with a lead plaintiff deadline of August 10, 2026. The case is pending in the United States — United States District Court for the Southern District of California.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard